Rheumatoid arthritis is a chronic disease of the joints, which causes joint pain and disability. Anaemia is a frequent extra-articular manifestation in rheumatoid arthritis, affecting 30-70% of the patients; presenting a negative impact on patient´s quality of life. Some of the drugs used in rheumatoid arthritis treatment improve anaemia; but little is known on the beneficial effects of the anti-rheumatic leflunomide or the anti-TNFα adalimumab, in this parameter. We investigated the incidence of anaemia in rheumatoid arthritis patients treated or not with leflunomide or adalimumab. We also assessed whether anaemia correlates with disease activity. Anaemia was present in patients who had just been diagnosed with rheumatoid arthritis and had never taken disease modifying agents or biologicals (non-specific therapy group), but not in those taking either leflunomide or adalimumab. The erythrocyte sedimentation rate was increased in patients with non-specific therapy in comparison with those taking either leflunomide or adalimumab. Anaemia correlated with increased erythrocyte sedimentation rate. We suggest that leflunomide and adalimumab may be useful in treating anaemia in patients with rheumatoid arthritis.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic disease of the joints, which causes joint pain and disability. Disease progression is characterized by intraarticular (pain and loss of joint function) and extra-articular manifestations of the disease. Anaemia is one of the most common extra-articular manifestations of RA, affecting 30-70% of the patients, and it has been linked to reduced quality of life (Song et al. 2013 , Ganna 2014 .
Also known as anaemia of inflammation, it can be triggered by increased release of cytokines, IONE C.P. PEREIRA et al. especially IL-6, in RA patients. Indeed, cytokine generation in RA has been associated with decreased iron availability, and increased absorption and retention within reticulo-endothelial cells; in addition to reduced numbers of red blood cells (for review see: Moreland and Curtis 2009, Masson 2011) . Although lowering of haemoglobin levels was found not be associated with chronic fatigue in RA patients, this response has been highly associated with disease activity (Singh et al. 2014) .
RA specific treatment comprises diseasemodifying anti-rheumatic drugs (DMARDs) and biologicals that aim to reduce joint inflammation and pain, thus attenuating disease progression. Although therapy targets the intra-articular manifestations of disease, some anti-rheumatic drugs are suggested to be useful in treating the extra-articular disease. These include some anti-TNFα inhibitors such as anakinra, rituximab (Nyhäll-Wåhlin et al. 2012 ) and etanercept (Calisto Pérez et al. 2012) ; and DMARDs such as methotrexate when used alone or in combination with a biological (Doyle et al. 2009 ). Indeed, these drugs were suggested to improve haemoglobin levels, whilst reducing rheumatoid nodules.
The DMARD leflunomide (LFN) and the anti-TNFα adalimumab (ADA) are currently used to treat RA in order to reduce joint pain and inflammation, however, little is known on the beneficial effects of these drugs in improving anaemia in RA patients. Here, we investigated the incidence of anaemia in RA patients treated or not with LFN or ADA. We also assessed whether anaemia correlates with different haematological and demographic parameters in these patients.
MATERIALS AND METHODS

PATIENTS
A total of 40 patients (men and women) aged > 30 years and clinically diagnosed with RA, were recruited for participation in the study. Patients included those who have just been diagnosed with RA but naïve for DMARDs and biologicals (n=10); patients under LFN (20 mg/day, per os, n=15) and patients under biological (ADA; 40 mg every 2 weeks, subcutaneously, n=15) therapy. Patients presented a score > 6 on the 2010 ACR-EULAR Classification Criteria For Rheumatoid Arthritis as previously detailed. Healthy subjects (n=15) were used as controls and included those who had no history of recent infections, malignancy or other autoimmune diseases and no present or previous use of DMARDs, biologicals or experimental drugs. We recorded demographics (age, gender and duration of disease), clinical (number of affected joints and presence or absence of rheumatoid nodules), and laboratory data. For laboratory data collection, five millilitres (ml) of peripheral blood were collected from each patient, in tubes containing ethylenediamine tetraacetic acid (EDTA) and used for automated analysis of red blood cell numbers, haemoglobin, haematocrit and erythrocyte sedimentation rate (ESR). The study was reviewed and approved by the Human Research Ethics Committee of the Universidade CEUMA and was performed in compliance with the Declaration of Helsinki. A written informed consent was obtained from each participant.
DATA ANALYSIS
The size of the experimental groups was calculated according to power analysis calculations in which power was ≥ 80%. Data are represented as mean and individual values obtained from each subject. Accordingly, we used parametric (ANOVA followed by Bonferroni´s test) test to determine the significance of differences between groups considering their mean + SD values. Correlations between the different parameters were determined using Spearman´s rho. Statistical analysis was undertaken using IBM SPSS Statistics 20. p values < 0.05 were considered statistically significant.
ANAEMIA TREATMENT BY LEFLUNOMIDE AND ADALIMUMAB 2163 RESULTS
SUBJECT CHARACTERISTICS
The majority of the arthritic population was comprised by women (75%; 30 out of 40). Arthritic patients had an average age of 50 years, with those under anti-rheumatic therapy presenting the highest averages (mean + SD were as follows: 40.5 + 8.4 for the NST group; 54.6 + 12.1 and 54.9 + 10.9, for the patients treated with LFN or ADA; respectively). Recently diagnosed arthritic patients (those receiving no specific treatment with antirheumatic drugs, NST group) presented disease for less than 2 years (mean + SD of 44.9 + 8.0) whilst those under treatment with LFN or ADA had disease symptoms for longer than 10 years (mean + SD of 54.6 + 12.1 and 51.0 + 13.6; for LFN and ADA patients, respectively). The number of swollen joints was higher in patients recently diagnosed (11.0 + 2.7) in comparison with those of patients under LFN (8.3 + 3.1) or ADA (7.3 + 2.9) therapy. The incidence of rheumatoid nodules was higher in patients receiving LFN or ADA (53% and 80%, respectively), in comparison with patients recently diagnosed (30%) with RA. The majority of the subjects composing the population of healthy subjects were women (73%) with an average age of 40 years.
TREATMENT WITH EITHER LFN OR ADA ATTENUATES ANAEMIA IN RA PATIENTS
As shown in Figure 1a , healthy subjects and RA patients presented similar numbers of red blood cells. However, the NST group presented lower levels of haemoglobin (15%) in comparison with those of healthy subjects (Figure 1b) . A similar reduction was observed for hematocrit although this response was not significant (Figure 1c) . RA patients treated with either LFN or ADA presented haemoglobin and hematrocit levels similar to those found in healthy subjects (Figure 1b, c) . Additionally, the NST group exhibited higher ESR (16.7-fold increase) when compared with healthy subjects (Figure 1d 
DISCUSSION
Anaemia is common in RA patients and it has been linked with disease activity (Smyrnova 2014). At least three pathophysiological pathways are associated with this extra-articular manifestation of RA, all involving cytokine production. Indeed, increased activation of inflammatory cells during the establishment and progression of disease, leads to an excessive production of cytokines such as TNFα, IL-1β and IL-6 (Moreland and Curtis 2009). In turn, these cytokines act on erythropoietic progenitor cells promoting haemolysis and subsequent reduction in the numbers of circulating red blood cells (Papadaki et al. 2002 , Masson 2011 . It has also been suggested that cytokine production in RA leads to reduction in the availability of iron (Spivak 2000 , Masson 2011 . This response has been associated with increased production of lactoferrin by activated neutrophils and increased iron absorption and retention within cells of the reticulo-endothelial system, leading to low circulating iron levels and low serum binding capacity. Although oral iron supplementation may be economic and safe for treating RA-related anaemia, only 50% of the patients respond to this therapy (van Santen et al. 2014) . Recent evidence has suggested that treatment of inflammation itself, may improve anaemia in RA. Indeed, anti-TNF therapy (Papadaki et al. 2002 , Calisto Pérez et al. 2012 , Sakthiswary et al. 2012 , Furst et al. 2013 ) administered alone or combined with DMARDs (Doyle et al. 2009 ) is suggested to improve haemoglobin levels in RA. However, little is known of LFN and ADA effects on anaemia. Indeed, a single study performed by Sakthiswary et al. (2012) recently demonstrated that RA patients treated with ADA exhibited improved levels of haemoglobin. Here, we present evidence on that both LFN and ADA treatments are able to attenuate anaemia in RA patients, denoted by increase in the levels of haemoglobin and decrease in the ESR. It is important to highlight that our study and the one by Sakthiswary et al. (2012) were performed in two very distinct populations (Malaysian x Brazilian), indicating that RA patients of different genetic backgrounds may benefit of ADA effects on anaemia. On the other hand, to the best of our knowledge, we present the first evidences on that LFN may be useful in treating RA-related anaemia.
Additionally, none of the treatments affected the number of red blood cells. Indeed, similar numbers of red blood cells were observed in all tested groups. These data suggest that anaemia in the evaluated patients is primarily related to increased iron retention or absorption within the reticulo-endothelial cells rather than haemolysis of erythropoietic progenitor cells.
We also found that the numbers of affected joints weakly correlate with the levels of haemoglobin in the NST group and in LFN-but not ADAtreated patients. Also, no significant correlations were observed between haemoglobin or ESR and the incidence of rheumatoid nodules. We suggest that anaemia may present a stronger correlation with other markers of disease activity, such as rheumatoid factor or C-reactive protein levels, pain, disability, amongst others. This hypothesis is supported by previous literature (Song et al. 2013) .
LFN or ADA effects on anaemia may be related to their inhibitory actions on inflammation, including on cytokine generation. LFN is known to block T cell proliferation by inhibiting the synthesis of pyrimidine (Fragoso and Brooks 2015) , and to reduce the activation of peripheral blood mononuclear cells (Grisar et al. 2004) . ADA was also shown to reduce peripheral blood leukocyte (monocytes and PMNs) activation (Ríos-Navarro et al. 2015) and to inhibit T cell proliferation (Vos et al. 2011) . All these suppressive effects on different cytokine-producing inflammatory cells may in turn be responsible for the attenuation of the anaemia in RA patients treated with LFN or ADA.
Overall, we present evidence on that treatment with LFN or ADA improves anaemia in RA, in addition to attenuating intra-articular damage, pain and disability. This is of importance as not all RA patients respond to iron supplementation.
